Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
Holding CLDX?
Track your performance easily
CLDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.93 - $53.18
Previous Close$26.22
Volume131.50K
Average Volume (3M)1.12M
Market Cap
$1.79B
Enterprise Value$986.63M
Total Cash (Recent Filing)$756.00M
Total Debt (Recent Filing)$3.09M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Mar 03, 2025EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding66,344,236
10 Day Avg. Volume1,037,768
30 Day Avg. Volume1,119,257
Standard Deviation0.53
R-Squared0.02
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)2.23
Price to Sales (P/S)166.13
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue98.90
Enterprise Value/Gross Profit143.34
Enterprise Value/Ebitda-6.70
Forecast
1Y Price Target
$65.70Price Target Upside143.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Celldex News
PremiumCompany Announcements
Celldex Therapeutics Reports Q3 2024 Progress and Financials
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCelldex announced positive topline results from its Phase 2 clinical study evaluating barzolvolimab in chronic inducible urticaria, meeting its primary endpoint with significant improvements in patient outcomes.
Investor ConfidenceCelldex's shares were up 7.61%, indicating a favorable reaction from investors to the company's recent announcements and clinical trial progress.
Therapeutic PotentialBarzolvolimab demonstrated significant improvement in angioedema in CSU patients, showing best-in-class efficacy and positioning it as a potential leading therapy for urticaria.
Bears Say
Market CompetitionPotential approvals for Xolair biosimilars, Dupixent, and remibrutinib will likely confine barzo exclusively to 2L+, which is a smaller opportunity than projected.
Patient ComplianceHigh discontinuation rates suggest lower patient compliance and effective drug price.
Safety ConcernsBarzo’s on-target neutropenia, hair discoloration, and other side effects could affect utilization by many patients/clinicians.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLDX FAQ
What was Celldex Therapeutics Inc’s price range in the past 12 months?
Celldex Therapeutics Inc lowest stock price was $22.93 and its highest was $53.18 in the past 12 months.
What is Celldex Therapeutics Inc’s market cap?
Currently, no data Available
When is Celldex Therapeutics Inc’s upcoming earnings report date?
Celldex Therapeutics Inc’s upcoming earnings report date is Mar 03, 2025 which is in 100 days.
How were Celldex Therapeutics Inc’s earnings last quarter?
Celldex Therapeutics Inc released its earnings results on Nov 06, 2024. The company reported -$0.64 earnings per share for the quarter, beating the consensus estimate of -$0.673 by $0.033.
Is Celldex Therapeutics Inc overvalued?
According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued.
Does Celldex Therapeutics Inc pay dividends?
Celldex Therapeutics Inc does not currently pay dividends.
What is Celldex Therapeutics Inc’s EPS estimate?
Celldex Therapeutics Inc’s EPS estimate is -$0.73.
How many shares outstanding does Celldex Therapeutics Inc have?
Celldex Therapeutics Inc has 66,344,240 shares outstanding.
What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?
Celldex Therapeutics Inc reported an EPS of -$0.64 in its last earnings report, beating expectations of -$0.673. Following the earnings report the stock price went down -4.198%.
Which hedge fund is a major shareholder of Celldex Therapeutics Inc?
Among the largest hedge funds holding Celldex Therapeutics Inc’s share is Woodline Partners LP. It holds Celldex Therapeutics Inc’s shares valued at 80M.
---
Celldex Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.70 (143.29% Upside)
$65.70 (143.29% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 23.8%
Last 30 Days ▲ 23.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.39%
12-Months-Change
Fundamentals
Return on Equity
-29.84%
Trailing 12-Months
Asset Growth
193.72%
Trailing 12-Months
Company Description
Celldex Therapeutics Inc
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
---
CLDX Stock 12 Month Forecast
Average Price Target
$65.70
▲(143.29% Upside)
Technical Analysis
Best Analysts Covering CLDX
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+98.46%
reiterated a buy rating 17 days ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +98.46% per trade.
---